Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 18, 2007 Brian Orelli	Amylin: Waiting on the Future Research and development costs drag down the drug developer's bottom line. Investors, take note.
The Motley Fool January 28, 2010 Brian Orelli	The Next Amgen? Not Yet. Amylin Pharmaceuticals is in much the same situation as Amgen is in: relatively flat sales, and the potential for a nice boost from a Food and Drug Administration approval shortly. But that's where the comparison ends.
The Motley Fool June 18, 2010 Brian Orelli	Hot Dog! No Competition for Now Roche's diabetes pipeline drug is delayed.
The Motley Fool January 27, 2011 Brian Orelli	Amylin Timeline Shortened -- Maybe Revenue down 6% year over year. Prescriptions of the company's top-selling drug, Byetta, down 5.9% quarter over quarter. Amylin Pharmaceuticals' fourth quarter wasn't pretty.
The Motley Fool June 11, 2008 Brian Orelli	Amylin's Down and Up on Diabetes Investors may be over-reacting to news both good and bad from Amylin Pharmaceuticals.
The Motley Fool June 16, 2010 Brian Orelli	A Drop on Bad News, but It Was a Long Shot Anyway Bydureon, Amylin Pharmaceuticals and Eli Lilly's once-weekly version of their twice-daily Byetta, has been beating up other diabetes drugs in a series of head-to-head clinical trials but it will have a tough time going after the monotherapy market.
The Motley Fool July 22, 2008 Brian Orelli	Anemic Amylin's Signs of Recovery Sales of Amylin Pharmaceuticals' diabetes drug Byetta have slowed over the last few quarters, but the company seems to be turning things around.
The Motley Fool April 17, 2009 Brian Orelli	Cost-Cutting? Check. Increased Sales? Hmm ... Amylin has half the equation. Now it needs the other half.
The Motley Fool October 19, 2006 Brian Lawler	Amylin's One-Drug Wonder Unfortunately, with research and development costs growing to $54 million from $33 million last year, Amylin is still a few quarters away from profitability. Diabetes drug Byetta is set to boost Amylin's sales. Investors, take note.
The Motley Fool April 16, 2010 Brian Orelli	It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet.
The Motley Fool December 12, 2008 Brian Orelli	Amylin Gets Some FDA Love Amylin's once-weekly diabetes drug Byetta gets a green light from the FDA.
The Motley Fool March 27, 2009 Brian Orelli	The Skinny on a Triple-Decker Update Amylin's public relations department might need to go on a diet.
The Motley Fool October 20, 2010 Brian Orelli	There Are No Safe Biotech Investments Amylin Pharmaceuticals and its partners, Eli Lilly and Alkermes, announced yesterday evening that the Food and Drug Administration had asked for more data before approving its once-weekly diabetes drug Bydureon.
The Motley Fool March 15, 2010 Brian Orelli	FDA Says "No Way!" Market Says "Yeah, Baby!" You can have it both ways. The Food and Drug Administration's response wasn't exactly what investors in Amylin Pharmaceuticals, Eli Lilly, and Alkermes were looking for, but they'll take it.
The Motley Fool January 29, 2008 Brian Orelli	No Weight Loss at Amylin Bulging costs related to its diabetes drug Byetta keep the drugmaker from showing a profit this quarter.
The Motley Fool April 20, 2010 Brian Orelli	Drug Sales Down! Should We Celebrate? Amylin won't have completed results for a trial comparing Bydureon to Victoza until next year. But until that data is in, it might not be as easy to get the patients back as Amylin is making it out to be.
The Motley Fool September 10, 2008 Brian Orelli	1 Drug Beats Another, but Who Will Care? Amylin Pharmaceuticals and Eli Lilly are fighting an uphill battle as they try to convince diabetics that the benefit from the two-needle-prick regimen of Byetta is worth the effort over popping a single pill.
The Motley Fool November 5, 2008 Brian Orelli	A Byetta Beating The FDA gives Amylin and Alkermes a smack down, but neither company is knocked out yet.
The Motley Fool March 3, 2011 Brian Orelli	Amylin Comes Up Snake Eyes Amylin Pharmaceuticals and partners Eli Lilly and Alkermes announced results of their head-to-head clinical trial comparing Bydureon with Novo Nordisk's diabetes drug Victoza.
The Motley Fool April 15, 2011 Brian Orelli	Fewer Needle Pricks for the Europeans Amylin's once-weekly diabetes drug Bydureon gets a positive recommendation in Europe.
The Motley Fool January 26, 2010 Brian Orelli	Is Victoza's Victory in Vain? Novo Nordisk finally gets the FDA to sign off on its once-daily diabetes drug.
The Motley Fool June 9, 2008 Brian Lawler	Novo Nordisk's Daring Success Novo Nordisk's potential blockbuster compound excels in late-stage head-to-head testing. Investors, take note.
The Motley Fool July 22, 2009 Brian Orelli	The Blockbuster Around the Corner Amylin Pharmaceuticals' Byetta sales are improving, but is it enough?
The Motley Fool March 5, 2008 Brian Orelli	FDA (Indirectly) Thwacks Amylin The FDA's draft guidance puts a cloud of uncertainty over the makers of diabetes drugs.
The Motley Fool September 20, 2010 Brian Orelli	Potential Blockbuster, No Me-Too About It A diabetes-fighting duo do it right this time.
The Motley Fool May 16, 2011 Brian Orelli	Diabetes Drug Duo Duels It Out in Court Amylin sticks up to partner Eli Lilly.
The Motley Fool June 24, 2008 Brian Orelli	A Diabetes Drug Delivery Deal Several pharmaceutical companies compete to deliver a diabetes medication that can be taken orally or once-weekly.
The Motley Fool January 31, 2007 Brian Lawler	No Sickness for Amylin Sales of the drugmaker's type-2 diabetes drugs showed solid growth. Investors, take note.
The Motley Fool November 24, 2006 Brian Lawler	Amylin Gets Past the Formalities Following a formal approval from the EU for Byetta, Amylin can get down to business. Investors, take note.
The Motley Fool August 19, 2008 Brian Orelli	Too Much Punishment for Amylin Several more pancreatitis cases cause Amylin Pharmaceuticals' investors to panic.
The Motley Fool August 27, 2008 Brian Orelli	Amylin Answers, Investors Panic Amylin Pharmaceuticals' conference call about side effects of its diabetes treatment, Byetta, doesn't have the desired effect.
The Motley Fool October 21, 2011 Brian Orelli	Full of News, but Worth a 15% Gain? Amylin serves up an appetizer.
The Motley Fool October 22, 2008 Brian Orelli	Why Amylin Skipped Some Byetta Numbers Usually the company presents the individual sales numbers for its two diabetes drugs from the year-ago quarter for investors to compare. But this time they were conspicuously absent.
The Motley Fool November 21, 2007 Brian Orelli	Phase 2 Data to Sink Your Teeth Into Novo Nordisk releases encouraging phase 2 clinical data about its weight-loss/diabetes drug, liraglutide. Investors, take note.
The Motley Fool February 12, 2010 Brian Orelli	Don't Ignore This Potential Blockbuster Five trials later, Roche's diabetes drug taspoglutide seems like a winner.
The Motley Fool July 22, 2010 Brian Orelli	It's All About the Future for Amylin Its second quarter stank, but there's a lot up ahead.
The Motley Fool December 7, 2007 Brian Orelli	Amylin's Temporarily Worthless Label Expansion Amylin releases label expansion data that won't be useful for a few years. Investors, take note.
The Motley Fool November 26, 2010 Brian Orelli	Black Friday Biotech Bargains Drugmakers on sale.
The Motley Fool November 3, 2009 Brian Orelli	Amylin Scores a Hat Trick Amylin Pharmaceuticals got a triple dose of good news over the weekend.
The Motley Fool September 22, 2010 Brian Orelli	Better Buy: Amylin Pharmaceuticals or MannKind? It's a diabetes-drug showdown.
The Motley Fool July 8, 2011 Brian Orelli	Let's Just Hope For No More FDA Surprises Despite the government's worries, Bydureon doesn't cause heart issues.
The Motley Fool November 9, 2011 Brian Orelli	Byetta Breakup! Buying Opportunity? We all saw this coming. Amylin Pharmaceuticals and Eli Lilly decided staying together for the kids just wasn't worth it
The Motley Fool May 19, 2008 Brian Orelli	What Will Icahn Do With Amylin? Carl Icahn recently took an initial position now worth around $200 million in Amylin Pharmaceuticals, and stockholders must be wondering about his motivation for the purchase.
The Motley Fool February 20, 2009 Brian Orelli	The Skinny on Diabetes Drugs The goal of diabetes drugs is to get the patient's blood glucose levels under control, but one class of drugs, called GLP1 agonists, have a nice side effect: weight loss. Which pharma companies can benefit?
The Motley Fool December 9, 2008 Brian Orelli	FDA Dashes Amylin Investors' Hopes Shareholders are still waiting to hear how much longer it'll be before Amylin and Eli Lilly can submit the marketing application for the once-weekly version of diabetes drug Byetta.
The Motley Fool April 22, 2008 Brian Orelli	Amylin Treads Water One-drug wonders like Amylin Pharmaceuticals can't get away with stagnant growth.
The Motley Fool October 31, 2008 Brian Orelli	Disease Is Good for Novo Nordisk The Danish drugmaker is able to grow despite the Danish krone moving against the currencies that predominate its sales..
The Motley Fool September 28, 2009 Brian Orelli	Here We Go Again With Possible Side Effects The FDA says it has received 88 reports of pancreatitis in patients taking Merck's Januvia and Janumet.
The Motley Fool March 31, 2009 Brian Orelli	Amylin Smacks Down the Competition Amylin's once-weekly blood sugar controlling drug Byetta trounces the competition.
The Motley Fool July 9, 2010 Brian Orelli	2 Days, 1 Blockbuster, Fate Unknown GlaxoSmithKline heads before a marathon two-day Food and Drug Administration advisory panel review of its diabetes drug Avandia.